426 related articles for article (PubMed ID: 32865781)
21. Knockdown of nuclear-retained long noncoding RNAs using modified DNA antisense oligonucleotides.
Zong X; Huang L; Tripathi V; Peralta R; Freier SM; Guo S; Prasanth KV
Methods Mol Biol; 2015; 1262():321-31. PubMed ID: 25555591
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides.
Løvendorf MB; Holm A; Petri A; Thrue CA; Uchida S; Venø MT; Kauppinen S
Nucleic Acid Ther; 2023 Jan; 33(1):45-57. PubMed ID: 36445751
[TBL] [Abstract][Full Text] [Related]
23. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
24. Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy.
Mahpour A; Mullen AC
JHEP Rep; 2021 Feb; 3(1):100177. PubMed ID: 33294829
[TBL] [Abstract][Full Text] [Related]
25. Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus.
Okamoto S; Echigoya Y; Tago A; Segawa T; Sato Y; Itou T
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834294
[TBL] [Abstract][Full Text] [Related]
26. Long noncoding RNAs and tumorigenesis: genetic associations, molecular mechanisms, and therapeutic strategies.
Zhang F; Zhang L; Zhang C
Tumour Biol; 2016 Jan; 37(1):163-75. PubMed ID: 26586396
[TBL] [Abstract][Full Text] [Related]
27. RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.
Mutso M; Nikonov A; Pihlak A; Žusinaite E; Viru L; Selyutina A; Reintamm T; Kelve M; Saarma M; Karelson M; Merits A
PLoS One; 2015; 10(6):e0128686. PubMed ID: 26039055
[TBL] [Abstract][Full Text] [Related]
28. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy.
Pant T; Dhanasekaran A; Fang J; Bai X; Bosnjak ZJ; Liang M; Ge ZD
BMC Cardiovasc Disord; 2018 Oct; 18(1):197. PubMed ID: 30342478
[TBL] [Abstract][Full Text] [Related]
29. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis.
Gao S; Zhao ZY; Wu R; Zhang Y; Zhang ZY
Onco Targets Ther; 2018; 11():4877-4891. PubMed ID: 30147339
[TBL] [Abstract][Full Text] [Related]
31. Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets?
Boon RA; Jaé N; Holdt L; Dimmeler S
J Am Coll Cardiol; 2016 Mar; 67(10):1214-1226. PubMed ID: 26965544
[TBL] [Abstract][Full Text] [Related]
32. Long Noncoding RNAs as Therapeutic Targets.
Pierce JB; Zhou H; Simion V; Feinberg MW
Adv Exp Med Biol; 2022; 1363():161-175. PubMed ID: 35220570
[TBL] [Abstract][Full Text] [Related]
33. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
Molecules; 2018 May; 23(6):. PubMed ID: 29844255
[TBL] [Abstract][Full Text] [Related]
34. Long noncoding RNAs in patients with acute myocardial infarction.
Vausort M; Wagner DR; Devaux Y
Circ Res; 2014 Sep; 115(7):668-77. PubMed ID: 25035150
[TBL] [Abstract][Full Text] [Related]
35. The role of lncRNAs/miRNAs/Sirt1 axis in myocardial and cerebral injury.
Barangi S; Hayes AW; Karimi G
Cell Cycle; 2023 May; 22(9):1062-1073. PubMed ID: 36703306
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNAs: a new frontier in the study of human diseases.
Shi X; Sun M; Liu H; Yao Y; Song Y
Cancer Lett; 2013 Oct; 339(2):159-66. PubMed ID: 23791884
[TBL] [Abstract][Full Text] [Related]
37. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
[TBL] [Abstract][Full Text] [Related]
38. Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Oligonucleotides; 2007; 17(3):291-301. PubMed ID: 17854269
[TBL] [Abstract][Full Text] [Related]
39. Circulating long non-coding RNAs NKILA, NEAT1, MALAT1, and MIAT expression and their association in type 2 diabetes mellitus.
Alfaifi M; Ali Beg MM; Alshahrani MY; Ahmad I; Alkhathami AG; Joshi PC; Alshehri OM; Alamri AM; Verma AK
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33436407
[TBL] [Abstract][Full Text] [Related]
40. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
